Get the Stockscreener App
10.97
2.49%
-0.28
After Hours:
10.97
Bicara Therapeutics Inc stock is traded at $10.97, with a volume of 261.55K.
It is down -2.49% in the last 24 hours and down -5.76% over the past month.
Bicara Therapeutics Inc is a clinical-stage biopharmaceutical company bringing transformative bifunctional therapies to patients with solid tumors. Its program ficerafusp alfa is a bifunctional antibody that combines two clinically validated targets, an epidermal growth factor receptor, or EGFR, directed monoclonal antibody with a domain that binds to human transforming growth factor beta, or TGF-b.
See More
Previous Close:
$11.25
Open:
$11.3
24h Volume:
261.55K
Relative Volume:
0.64
Market Cap:
$598.55M
Revenue:
-
Net Income/Loss:
-
P/E Ratio:
-
EPS:
-
Net Cash Flow:
-
1W Performance:
-8.05%
1M Performance:
-5.76%
6M Performance:
-18.74%
1Y Performance:
-59.48%
1-Day Range:
$10.81
$11.55
1-Week Range:
$10.81
$12.10
52-Week Range:
$7.80
$28.09
Bicara Therapeutics Inc Stock (BCAX) Company Profile
Name
Bicara Therapeutics Inc
Sector
Industry
Phone
617-468-4219
Address
116 HUNTINGTON AVENUE SUITE 703, BOSTON
Compare BCAX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
BCAX
Bicara Therapeutics Inc
|
10.97 | 613.83M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
387.15 | 100.34B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
585.50 | 60.95B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
451.73 | 60.46B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
734.35 | 46.04B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
332.20 | 36.02B | 3.81B | -644.79M | -669.77M | -6.24 |
Bicara Therapeutics Inc Stock (BCAX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-19-25 | Initiated | Piper Sandler | Overweight |
| May-23-25 | Upgrade | Wells Fargo | Underweight → Equal Weight |
| Apr-17-25 | Initiated | Wells Fargo | Underweight |
| Feb-06-25 | Initiated | Wedbush | Outperform |
| Dec-06-24 | Initiated | H.C. Wainwright | Buy |
| Nov-05-24 | Initiated | Rodman & Renshaw | Buy |
| Oct-08-24 | Initiated | Cantor Fitzgerald | Overweight |
| Oct-08-24 | Initiated | Morgan Stanley | Overweight |
| Oct-08-24 | Initiated | Stifel | Buy |
| Oct-08-24 | Initiated | TD Cowen | Buy |
View All
Bicara Therapeutics Inc Stock (BCAX) Latest News
Technical analysis overview for Bicara Therapeutics Inc. stockJuly 2025 Intraday Action & Low Drawdown Investment Strategies - newser.com
Using flow based indicators on Bicara Therapeutics Inc.Weekly Trade Report & Safe Capital Growth Trade Ideas - newser.com
What does recent volatility data suggest for Bicara Therapeutics Inc.July 2025 Decliners & Community Trade Idea Sharing Platform - newser.com
Is a relief rally coming for Bicara Therapeutics Inc. holdersPortfolio Risk Report & Free Long-Term Investment Growth Plans - newser.com
Hedge Fund Moves: Should you avoid Bicara Therapeutics Inc stock right nowRecession Risk & Free Fast Entry Momentum Trade Alerts - خودرو بانک
Day Trade: Is Bicara Therapeutics Inc a top pick in the sectorMarket Activity Summary & Free Expert Verified Stock Movement Alerts - خودرو بانک
Gap Down: What are analysts price targets for Bicara Therapeutics IncJuly 2025 Intraday Action & Low Drawdown Trading Strategies - خودرو بانک
Bond Watch: Is Bicara Therapeutics Inc a top pick in the sectorAnalyst Downgrade & Daily Market Momentum Tracking - خودرو بانک
Aug Wrap: Is Bicara Therapeutics Incs growth already priced inOil Prices & Safe Entry Momentum Stock Tips - خودرو بانک
Analyzing recovery setups for Bicara Therapeutics Inc. investorsEarnings Recap Summary & Expert Verified Stock Movement Alerts - newser.com
Geopolitics Watch: What is the earnings history of Bicara Therapeutics IncEarnings Miss & Growth-Oriented Investment Plans - خودرو بانک
Whale Trades: How much upside does Bicara Therapeutics Inc haveEarnings Performance Report & Long-Term Capital Growth Strategies - خودرو بانک
Applying sector rotation models to Bicara Therapeutics Inc.Earnings Trend Report & Precise Swing Trade Entry Alerts - newser.com
Heatmap analysis for Bicara Therapeutics Inc. and competitors2025 Key Lessons & Weekly Top Gainers Alerts - newser.com
Bicara Therapeutics Inc. $BCAX Shares Sold by Adage Capital Partners GP L.L.C. - MarketBeat
Detecting support and resistance levels for Bicara Therapeutics Inc.2025 Volume Leaders & Technical Analysis for Trade Confirmation - Newser
Nuveen LLC Purchases Shares of 25,028 Bicara Therapeutics Inc. $BCAX - MarketBeat
How to forecast Bicara Therapeutics Inc. trends using time seriesWeekly Profit Summary & Risk Managed Investment Entry Signals - Newser
Bicara Therapeutics Inc. stock outlook for YEAR2025 Price Momentum & AI Enhanced Trading Alerts - Newser
Has Bicara Therapeutics Inc. formed a bullish divergence2025 Winners & Losers & High Accuracy Trade Alerts - Newser
What high frequency data says about Bicara Therapeutics Inc.Layoff News & Community Consensus Stock Picks - Newser
Sentiment analysis tools applied to Bicara Therapeutics Inc.July 2025 Breakouts & Daily Technical Stock Forecast Reports - Newser
Can Bicara Therapeutics Inc. rally from current levelsGlobal Markets & Daily Price Action Insights - Newser
Will Bicara Therapeutics Inc. continue its uptrend2025 Year in Review & Fast Entry and Exit Trade Plans - Newser
What momentum shifts mean for Bicara Therapeutics Inc.Entry Point & Stock Market Timing Techniques - Newser
Is Bicara Therapeutics Inc. stock entering bullish territoryQuarterly Profit Report & Stepwise Entry/Exit Trade Alerts - Newser
What’s the recovery path for long term holders of Bicara Therapeutics Inc. - Newser
Jones Trading initiates coverage on Bicara stock with Buy rating By Investing.com - Investing.com Canada
Jones Trading initiates coverage on Bicara stock with Buy rating - Investing.com
bicara therapeutics inc. stock outlook for yearStop Loss & Daily Profit Maximizing Tips - Newser
JonesTrading Initiates Bicara Therapeutics(BCAX.US) With Buy Rating, Announces Target Price $22 - 富途牛牛
Can machine learning forecast Bicara Therapeutics Inc. recoveryDay Trade & Daily Profit Maximizing Tips - Newser
Exit strategy if you’re trapped in Bicara Therapeutics Inc.Quarterly Market Review & Step-by-Step Trade Execution Guides - Newser
Backtesting results for Bicara Therapeutics Inc. trading strategiesTrade Risk Report & Safe Entry Point Identification - Newser
Is Bicara Therapeutics Inc. reversing from oversold territoryPortfolio Risk Summary & Weekly Breakout Watchlists - Newser
Visualizing Bicara Therapeutics Inc. stock with heatmaps2025 Year in Review & Long-Term Capital Growth Ideas - Newser
Using fundamentals and technicals on Bicara Therapeutics Inc.Quarterly Performance Summary & Smart Allocation Stock Tips - Newser
Published on: 2025-09-09 04:32:28 - Newser
Risk vs reward if holding onto Bicara Therapeutics Inc.July 2025 Closing Moves & Weekly High Return Forecasts - Newser
How moving averages guide Bicara Therapeutics Inc. tradingJuly 2025 News Drivers & Free High Accuracy Swing Entry Alerts - Newser
Ranking Bicara Therapeutics Inc. among high performing stocks via toolsWeekly Investment Recap & Consistent Return Investment Signals - Newser
Bicara Therapeutics Inc. stock volume spike explainedQuarterly Trade Summary & Risk Managed Investment Entry Signals - Newser
Published on: 2025-09-09 00:38:18 - Newser
historical volatility pattern of bicara therapeutics inc. visualizedJuly 2025 Snapshot & Daily Profit Focused Screening - Newser
Published on: 2025-09-08 20:23:35 - Newser
How to track smart money flows in Bicara Therapeutics Inc.Quarterly Trade Summary & Fast Moving Stock Watchlists - Newser
Published on: 2025-09-08 15:28:10 - Newser
Will Bicara Therapeutics Inc. benefit from macro trendsStock Surge & AI Based Buy and Sell Signals - Newser
Bicara Therapeutics Inc Stock (BCAX) Financials Data
There is no financial data for Bicara Therapeutics Inc (BCAX). Check out other stocks for more information.
Revenue
Net Income
Cash Flow
EPS
0.62%
0.57%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):